| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rúbia W de Oliveira, Cilene L Oliveira, Francisco S Guimarães, Alline C Campo. Cannabinoid signalling in embryonic and adult neurogenesis: possible implications for psychiatric and neurological disorders. Acta neuropsychiatrica. vol 31. issue 1. 2019-04-17. PMID:29764526. |
the text offers an overview on the effects of cannabinoids on central nervous system development and the possible links with psychiatric and neurological disorders such as anxiety, depression, schizophrenia, brain ischaemia/stroke and alzheimer's disease. |
2019-04-17 |
2023-08-13 |
Not clear |
| Pedro González-Naranjo, Natalia Pérez-Macias, Concepción Pérez, Carlos Roca, Gabriela Vaca, Rocio Girón, Eva Sánchez-Robles, María Isabel Martín-Fontelles, María L de Ceballos, Angeles Martin-Requero, Nuria E Campillo, Juan A Páe. Indazolylketones as new multitarget cannabinoid drugs. European journal of medicinal chemistry. vol 166. 2019-03-05. PMID:30685536. |
multitarget cannabinoids could be a promising therapeutic strategic to fight against alzheimer's disease. |
2019-03-05 |
2023-08-13 |
human |
| Jian Zhang, Chu Che. Alleviation of Neuropathology by Inhibition of Monoacylglycerol Lipase in APP Transgenic Mice Lacking CB2 Receptors. Molecular neurobiology. vol 55. issue 6. 2019-02-11. PMID:28733897. |
inhibition of monoacylglycerol lipase (magl), the primary enzyme that hydrolyzes the endocannabinoid 2-arachidonoylglycerol (2-ag) in the brain, produces profound anti-inflammatory and neuroprotective effects and improves synaptic and cognitive functions in animal models of alzheimer's disease (ad). |
2019-02-11 |
2023-08-13 |
mouse |
| Ewa Poleszak, Sylwia Wośko, Karolina Sławińska, Aleksandra Szopa, Andrzej Wróbel, Anna Serefk. Cannabinoids in depressive disorders. Life sciences. vol 213. 2018-12-11. PMID:30290188. |
benefits from use of cannabinoid agents in epilepsy, multiple sclerosis, parkinson's disease, alzheimer's disease, and others have been suggested. |
2018-12-11 |
2023-08-13 |
Not clear |
| Alexandros G Asimakopoulos, Pranav Kannan, Sean Higgins, Kurunthachalam Kanna. Determination of 89 drugs and other micropollutants in unfiltered wastewater and freshwater by LC-MS/MS: an alternative sample preparation approach. Analytical and bioanalytical chemistry. vol 409. issue 26. 2018-04-30. PMID:28815276. |
the target chemicals fall under the classes of amphetamine-type stimulants, cocaine compounds, opiates and opioids, benzodiazepines, lysergic compounds, antipsychotics, anesthetics, antiepileptics, antidepressants, sympathomimetics, cannabinoids, blood thinners, antihistamines, β-blockers, caffeine derivatives, nicotine derivatives, z-drugs, new designer drugs, and alzheimer medications. |
2018-04-30 |
2023-08-13 |
Not clear |
| Attila Köfalvi, Cristina Lemos, Ana M Martín-Moreno, Bárbara S Pinheiro, Luis García-García, Miguel A Pozo, Ângela Valério-Fernandes, Rui O Beleza, Paula Agostinho, Ricardo J Rodrigues, Susana J Pasquaré, Rodrigo A Cunha, María L de Ceballo. Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease. Neuropharmacology. vol 110. issue Pt A. 2018-02-22. PMID:26976670. |
stimulation of brain glucose uptake by cannabinoid cb2 receptors and its therapeutic potential in alzheimer's disease. |
2018-02-22 |
2023-08-13 |
mouse |
| Tomoyo Imamura, Kazuhiro Tsuruma, Yuki Inoue, Tomohiro Otsuka, Yuta Ohno, Shiho Ogami, Shinsaku Yamane, Masamitsu Shimazawa, Hideaki Har. Rimonabant, a selective cannabinoid European journal of pharmacology. vol 803. 2017-11-21. PMID:28315677. |
rimonabant, a selective cannabinoid the endocannabinoid system is involved in some neurodegenerative diseases such as alzheimer's disease. |
2017-11-21 |
2023-08-13 |
Not clear |
| Rimplejeet Kaur, Sneha R Ambwani, Surjit Sing. Endocannabinoid System: A Multi-Facet Therapeutic Target. Current clinical pharmacology. vol 11. issue 2. 2017-09-04. PMID:27086601. |
several diseases like emesis, pain, inflammation, multiple sclerosis, anorexia, epilepsy, glaucoma, schizophrenia, cardiovascular disorders, cancer, obesity, metabolic syndrome related diseases, parkinson's disease, huntington's disease, alzheimer's disease and tourette's syndrome could possibly be treated by drugs modulating endocannabinoid system. |
2017-09-04 |
2023-08-13 |
human |
| Iván Manuel, Laura Lombardero, Frank M LaFerla, Lydia Giménez-Llort, Rafael Rodríguez-Puerta. Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer's disease. Neuroscience. vol 329. 2017-07-26. PMID:27223629. |
activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of alzheimer's disease. |
2017-07-26 |
2023-08-13 |
mouse |
| Serena Montanari, Laura Scalvini, Manuela Bartolini, Federica Belluti, Silvia Gobbi, Vincenza Andrisano, Alessia Ligresti, Vincenzo Di Marzo, Silvia Rivara, Marco Mor, Alessandra Bisi, Angela Ramp. Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. Journal of medicinal chemistry. vol 59. issue 13. 2017-05-29. PMID:27309570. |
in particular, indirectly enhancing endocannabinoid signaling to therapeutic levels through faah inhibition might be beneficial for neurodegenerative disorders such as alzheimer's disease, effectively preventing or slowing the progression of the disease. |
2017-05-29 |
2023-08-13 |
Not clear |
| Serena Montanari, Laura Scalvini, Manuela Bartolini, Federica Belluti, Silvia Gobbi, Vincenza Andrisano, Alessia Ligresti, Vincenzo Di Marzo, Silvia Rivara, Marco Mor, Alessandra Bisi, Angela Ramp. Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. Journal of medicinal chemistry. vol 59. issue 13. 2017-05-29. PMID:27309570. |
hence, in the search for a more effective treatment for alzheimer's disease, in this paper, the multitarget-directed ligand paradigm was applied to the design of carbamates able to simultaneously target the recently proposed endocannabinoid system and the classic cholinesterase system, and achieve effective dual faah/cholinesterase inhibitors. |
2017-05-29 |
2023-08-13 |
Not clear |
| Mauro Maccarrone, Rafael Maldonado, Miguel Casas, Thomas Henze, Diego Centonz. Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert review of clinical pharmacology. vol 10. issue 4. 2017-03-29. PMID:28276775. |
other diseases in which different cannabinoids are currently being investigated include various pain states, alzheimer's disease, parkinson's disease, huntington's disease and epilepsy. |
2017-03-29 |
2023-08-13 |
human |
| Rawaha Ahmad, Andrey Postnov, Guy Bormans, Jan Versijpt, Mathieu Vandenbulcke, Koen Van Laer. Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease. European journal of nuclear medicine and molecular imaging. vol 43. issue 12. 2017-02-21. PMID:27488857. |
decreased in vivo availability of the cannabinoid type 2 receptor in alzheimer's disease. |
2017-02-21 |
2023-08-13 |
Not clear |
| Raúl González-Domínguez, Francisco Javier Rupérez, Tamara García-Barrera, Coral Barbas, José Luis Gómez-Ariz. Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer's Disease and Mild Cognitive Impairment. Current Alzheimer research. vol 13. issue 6. 2017-01-03. PMID:26825096. |
furthermore, several discriminant metabolites were found for the first time in relation to known pathological processes associated with alzheimer's disease, such as the accumulation of acylcarnitines in relation to mitochondrial dysfunction, decreased levels of oleamide and monoglycerides as a result of defects in endocannabinoid system, or increased serum phenylacetylglutamine, which could reveal alterations in glutamine homeostasis. |
2017-01-03 |
2023-08-13 |
human |
| Ji Jia, Jie Peng, Zhaoju Li, Youping Wu, Qunlin Wu, Weifeng Tu, Mingchun W. Cannabinoid CB2 Receptor Mediates Nicotine-Induced Anti-Inflammation in N9 Microglial Cells Exposed to β Amyloid via Protein Kinase C. Mediators of inflammation. vol 2016. 2016-12-13. PMID:26884647. |
cannabinoid cb2 receptor mediates nicotine-induced anti-inflammation in n9 microglial cells exposed to β amyloid via protein kinase c. reducing β amyloid- (aβ-) induced microglial activation is considered to be effective in treating alzheimer's disease (ad). |
2016-12-13 |
2023-08-13 |
Not clear |
| Carmen Vázquez, Rosa M Tolón, M Teresa Grande, Marina Caraza, Marta Moreno, Erin C Koester, Borja Villaescusa, Lourdes Ruiz-Valdepeñas, Francisco Javier Fernández-Sánchez, Benjamin F Cravatt, Cecilia J Hillard, Julián Romer. Endocannabinoid regulation of amyloid-induced neuroinflammation. Neurobiology of aging. vol 36. issue 11. 2016-08-15. PMID:26362942. |
the modulation of endocannabinoid (ec) levels and the activation of cannabinoid receptors are seen as promising therapeutic strategies in a variety of diseases, including alzheimer's disease (ad). |
2016-08-15 |
2023-08-13 |
mouse |
| Javier Fernández-Ruiz, María A Moro, José Martínez-Orgad. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 12. issue 4. 2016-07-22. PMID:26260390. |
in this review, we will collect all experimental evidence, mainly obtained at the preclinical level, supporting that different cannabinoid compounds may be neuroprotective in adult and neonatal ischemia, brain trauma, alzheimer's disease, parkinson's disease, huntington's chorea, and amyotrophic lateral sclerosis. |
2016-07-22 |
2023-08-13 |
Not clear |
| Claudia Altamura, Mariacarla Ventriglia, Maria Giulia Martini, Domenico Montesano, Yuri Errante, Fabiana Piscitelli, Federica Scrascia, Carlo Quattrocchi, Paola Palazzo, Serenella Seccia, Fabrizio Vernieri, Vincenzo Di Marz. Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer's Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline. Journal of Alzheimer's disease : JAD. vol 46. issue 2. 2016-07-11. PMID:25818503. |
growing evidence suggests that the endocannabinoid system is involved in the pathogenesis of alzheimer's disease (ad) and atherosclerosis. |
2016-07-11 |
2023-08-13 |
Not clear |
| Celina S Liu, Sarah A Chau, Myuri Ruthirakuhan, Krista L Lanctôt, Nathan Herrman. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease. CNS drugs. vol 29. issue 8. 2016-07-06. PMID:26271310. |
cannabinoids for the treatment of agitation and aggression in alzheimer's disease. |
2016-07-06 |
2023-08-13 |
Not clear |
| E Aga. The role of cannabinoids and leptin in neurological diseases. Acta neurologica Scandinavica. vol 132. issue 6. 2016-05-26. PMID:25880465. |
cannabinoids exert a neuroprotective influence on some neurological diseases, including alzheimer's, parkinson's, huntington's, multiple sclerosis and epilepsy. |
2016-05-26 |
2023-08-13 |
Not clear |